Biogen Inc

7 bondsConsumer Non-Cyclical🇺🇸 US
Outstanding
Avg yield
5.49%
7 of 7 priced
Active bonds
7
Currencies
USD
Countries
US

About Biogen Inc

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), interferon beta-1a (AVONEX), peginterferon beta-1a (Plegridy), and natalizumab (Tysabri), all for the treatment of multiple sclerosis ; nusinersen (Spinraza) for the treatment of spinal muscular atrophy ; omaveloxolone (Skyclarys) for the treatment of Friedreich's ataxia ; tofersen (Qalsody) for the treatment of ALS; and dimethyl fumarate (Fumaderm) for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.

SOURCE: WIKIPEDIA →

Maturity ladder

Active bonds by year of maturity

2030
1
2031
1
2035
1
2045
1
2050
1
2051
1
2055
1

All bonds

IdentifierNameCouponMaturityCcyCountryPriceYieldAs of
US09062XAH61Biogen Inc 2.25% 05/20302.250%2030-05-01USD🇺🇸US91.514.62%2026-05-07
US09062XAN30Biogen Inc 5.05% 01/20315.050%2031-01-15USD🇺🇸US103.214.65%2026-05-07
US09062XAL73Biogen Inc 5.75% 05/20355.750%2035-05-15USD🇺🇸US107.105.14%2026-05-07
US09062XAD57Biogen Inc 5.2% 09/20455.200%2045-09-15USD🇺🇸US91.735.92%2026-05-07
US09062XAG88Biogen Inc 3.15% 05/20503.150%2050-05-01USD🇺🇸US64.026.00%2026-05-07
US09062XAK90Biogen Inc 3.25% 02/20513.250%2051-02-15USD🇺🇸US64.606.02%2026-05-07
US09062XAM56Biogen Inc 6.45% 05/20556.450%2055-05-15USD🇺🇸US105.216.07%2026-05-07
Currency mix
USD7 · 100%
Issuing countries
Ratings
S&P
BBB+
Moody's
Baa2
7 of 7 bonds rated